Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:54 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 526953 | NSE: VENUSREM

Venus Remedies Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹392.59Overvalued by 54.40%vs CMP ₹861.00

P/E (15.1) × ROE (7.2%) × BV (₹445.00) × DY (2.00%)

₹559.82Overvalued by 34.98%vs CMP ₹861.00
MoS: -53.8% (Negative)Confidence: 63/100 (Moderate)Models: 1 Under, 8 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹445.1523%Over (-48.3%)
Graham NumberEarnings₹756.0516%Over (-12.2%)
Earnings PowerEarnings₹180.6911%Over (-79%)
DCFCash Flow₹1,070.5314%Under (+24.3%)
Net Asset ValueAssets₹444.347%Over (-48.4%)
EV/EBITDAEnterprise₹510.179%Over (-40.7%)
Earnings YieldEarnings₹570.907%Over (-33.7%)
ROCE CapitalReturns₹314.967%Over (-63.4%)
Revenue MultipleRevenue₹478.755%Over (-44.4%)
Consensus (9 models)₹559.82100%Overvalued
Key Drivers: Wide model spread (₹181–₹1,071) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 13.4%

*Investments are subject to market risks

Investment Snapshot

67
Venus Remedies Ltd scores 67/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health70/100 · Strong
ROCE 11.1% AverageROE 7.2% AverageD/E 0.12 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money75/100 · Strong
FII holding up 0.91% (6mo) Slight increaseDII holding up 1.03% MF buyingPromoter holding at 41.8% Stable
Earnings Quality50/100 · Moderate
OPM stable around 10% Steady
Quarterly Momentum90/100 · Strong
Revenue (4Q): +8% YoY GrowingProfit (4Q): +114% YoY StrongOPM: 21.0% (up 11.0% YoY) Margin expansion
Industry Rank50/100 · Moderate
P/E 15.1 vs industry 53.8 Cheaper than peersROCE 11.1% vs industry 16.4% AverageROE 7.2% vs industry 15.2% Below peers3Y sales CAGR: 2% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:54 am

Market Cap 1,151 Cr.
Current Price 861
Intrinsic Value₹559.82
High / Low 950/286
Stock P/E15.1
Book Value 445
Dividend Yield0.00 %
ROCE11.1 %
ROE7.16 %
Face Value 10.0
PEG Ratio1.13

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Venus Remedies Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Venus Remedies Ltd 1,151 Cr. 861 950/28615.1 4450.00 %11.1 %7.16 % 10.0
Hester Biosciences Ltd 1,162 Cr. 1,366 2,350/1,23928.4 3970.51 %9.71 %9.18 % 10.0
Ind-Swift Laboratories Ltd 1,128 Cr. 138 152/67.223.8 1600.00 %0.78 %0.18 % 10.0
Lincoln Pharmaceuticals Ltd 1,191 Cr. 595 679/44013.6 3570.30 %17.3 %12.8 % 10.0
TTK Healthcare Ltd 1,107 Cr. 784 1,402/73515.9 7681.28 %9.26 %6.89 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Venus Remedies Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 11715695168143195109170177195137193180
Expenses 1091318515013117697163158166122162143
Operating Profit 825101812191181829153138
OPM % 7%16%11%11%8%10%10%4%10%15%11%16%21%
Other Income 43232428127323
Interest 0000000000000
Depreciation 7886766655667
Profit before tax 520514817792531132633
Tax % 28%44%77%31%12%40%82%61%21%32%24%24%24%
Net Profit 311110711142021102026
EPS in Rs 2.468.270.887.445.127.860.912.6314.6615.717.1815.0619.14

Last Updated: February 3, 2026, 4:16 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 9:16 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 531455407400372322335544597552596640705
Expenses 393366326349333289295490535492537577592
Operating Profit 1388981513933415462606064113
OPM % 26%20%20%13%11%10%12%10%10%11%10%10%16%
Other Income 01222-3-443810123114
Interest 294138343525131300000
Depreciation 40464240343432353432262324
Profit before tax 6934-22-28-30-84936384572104
Tax % 7%-95%52%-21%11%-4%24%-27%-12%30%36%37%
Net Profit 6452-17-31-29-10624127284576
EPS in Rs 56.204.511.49-13.84-24.87-23.15-8.1050.0530.4619.8821.3133.9057.09
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-92.19%-60.00%-950.00%-82.35%6.45%65.52%720.00%-33.87%-34.15%3.70%60.71%
Change in YoY Net Profit Growth (%)0.00%32.19%-890.00%867.65%88.80%59.07%654.48%-753.87%-0.28%37.85%57.01%

Venus Remedies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:3%
5 Years:14%
3 Years:2%
TTM:9%
Compounded Profit Growth
10 Years:22%
5 Years:69%
3 Years:-3%
TTM:64%
Stock Price CAGR
10 Years:15%
5 Years:36%
3 Years:30%
1 Year:31%
Return on Equity
10 Years:2%
5 Years:8%
3 Years:6%
Last Year:7%

Last Updated: September 5, 2025, 1:51 pm

Balance Sheet

Last Updated: December 4, 2025, 2:11 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 11111112121212121313131313
Reserves 450445426376350320311388427447474548581
Borrowings 28932133531230729822051434241214
Other Liabilities 8464706582102100104979898153159
Total Liabilities 834841843765751733644556580601627716768
Fixed Assets 439444452406389364289262241216219229237
CWIP 68788066656525252526212634
Investments 000000000201984193
Other Assets 327319310293297304330269314339368376303
Total Assets 834841843765751733644556580601627716768

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 5368475931457813241373786
Cash from Investing Activity + -95-673-188-11-557-17-58-8-77
Cash from Financing Activity + 40-1-46-44-39-35-73-162-9-1-1-1
Net Cash Flow -2-13-40-1-02714-22289
Free Cash Flow 3559464119357013241292469
CFO/OP 38%76%58%116%79%139%190%245%66%61%89%160%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-151.00-232.00-254.00-261.00-268.00-265.00-179.003.0019.0018.0019.0062.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 455155434643332124514964
Inventory Days 17319421922624628629612911813212597
Days Payable 384038485272777647565589
Cash Conversion Cycle 180204236221240257252749512712072
Working Capital Days 3954695425-173718210911886
ROCE %14%6%5%2%1%1%2%8%8%8%9%11%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%
FIIs 1.00%0.98%1.03%1.59%1.48%1.06%1.18%1.11%1.34%2.25%1.86%2.25%
DIIs 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.11%0.75%1.03%
Public 57.26%57.26%57.21%56.65%56.76%57.17%57.06%57.13%56.90%55.89%55.62%54.95%
No. of Shareholders 21,71920,49819,26719,56019,91319,61419,55719,77119,98219,30717,72518,606

Shareholding Pattern Chart

No. of Shareholders

Venus Remedies Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 33.9021.3119.8830.8650.04
Diluted EPS (Rs.) 33.9021.3119.8830.8650.04
Cash EPS (Rs.) 50.7441.1044.0455.5578.63
Book Value[Excl.RevalReserv]/Share (Rs.) 419.65364.74344.38329.50324.33
Book Value[Incl.RevalReserv]/Share (Rs.) 419.65364.74344.38329.50324.33
Revenue From Operations / Share (Rs.) 484.69449.95415.58447.86444.11
PBDIT / Share (Rs.) 63.2053.2552.7652.6859.48
PBIT / Share (Rs.) 46.3733.4728.6027.6030.90
PBT / Share (Rs.) 53.7333.4028.3827.2439.34
Net Profit / Share (Rs.) 33.9021.3119.8730.4750.04
NP After MI And SOA / Share (Rs.) 33.9021.3119.8730.4750.04
PBDIT Margin (%) 13.0411.8312.6911.7613.39
PBIT Margin (%) 9.567.436.886.166.95
PBT Margin (%) 11.087.426.826.088.85
Net Profit Margin (%) 6.994.734.786.8011.26
NP After MI And SOA Margin (%) 6.994.734.786.8011.26
Return on Networth / Equity (%) 8.075.845.779.2415.43
Return on Capital Employeed (%) 10.698.177.377.578.31
Return On Assets (%) 6.334.544.417.0211.11
Long Term Debt / Equity (X) 0.000.070.080.080.11
Total Debt / Equity (X) 0.000.080.090.090.12
Asset Turnover Ratio (%) 0.960.970.901.010.86
Current Ratio (X) 3.314.533.913.002.38
Quick Ratio (X) 2.582.992.461.641.15
Inventory Turnover Ratio (X) 5.832.852.653.042.64
Interest Coverage Ratio (X) 1291.82759.66239.55146.415.64
Interest Coverage Ratio (Post Tax) (X) 542.31305.0691.2485.673.94
Enterprise Value (Cr.) 322.06409.53205.06351.82361.07
EV / Net Operating Revenue (X) 0.490.680.360.580.65
EV / EBITDA (X) 3.815.752.915.004.92
MarketCap / Net Operating Revenue (X) 0.610.720.380.600.61
Price / BV (X) 0.710.890.470.810.84
Price / Net Operating Revenue (X) 0.610.720.380.600.61
EarningsYield 0.110.060.120.110.18

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Venus Remedies Ltd. is a Public Limited Listed company incorporated on 15/09/1989 and has its registered office in the State of Chandigarh, India. Company's Corporate Identification Number(CIN) is L24232CH1989PLC009705 and registration number is 009705. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 639.46 Cr. and Equity Capital is Rs. 13.37 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsS.C.O. 857, C. No. 10, 2nd Floor, NAC Manimajra, Chandigarh Chandigarh 160101Contact not found
Management
NamePosition Held
Mr. Pawan ChaudharyChairman & Managing Director
Dr.(Mrs.) Manu ChaudharyJoint Managing Director
Mr. Peeyush JainDeputy Managing Director
Mr. Ashutosh JainExecutive Director
Mr. Akshansh ChaudharyExecutive Director
Dr.(Mrs.) Savita GuptaIndependent Director
Mr. N P S MongaIndependent Director
Mr. Navdeep SudIndependent Director
Mr. Jagdish Chander SharmaIndependent Director
Dr. Anil KumarIndependent Director

FAQ

What is the intrinsic value of Venus Remedies Ltd and is it undervalued?

As of 03 April 2026, Venus Remedies Ltd's intrinsic value is ₹559.82, which is 34.98% lower than the current market price of ₹861.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (7.16 %), book value (₹445), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Venus Remedies Ltd?

Venus Remedies Ltd is trading at ₹861.00 as of 03 April 2026, with a FY2026-2027 high of ₹950 and low of ₹286. The stock is currently near its 52-week high. Market cap stands at ₹1,151 Cr..

How does Venus Remedies Ltd's P/E ratio compare to its industry?

Venus Remedies Ltd has a P/E ratio of 15.1, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Venus Remedies Ltd financially healthy?

Key indicators for Venus Remedies Ltd: ROCE of 11.1 % is moderate; ROE of 7.16 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Venus Remedies Ltd profitable and how is the profit trend?

Venus Remedies Ltd reported a net profit of ₹45 Cr in Mar 2025 on revenue of ₹640 Cr. Compared to ₹41 Cr in Mar 2022, the net profit shows an improving trend.

Does Venus Remedies Ltd pay dividends?

Venus Remedies Ltd has a dividend yield of 0.00 % at the current price of ₹861.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Venus Remedies Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports